Skip to Content

10x Genomics stock falls as revenue forecast disappoints

Shares of 10x Genomics Inc. (TXG) fell in the extended session Thursday after the biotech company said it expects second-quarter revenue to come in below Wall Street expectations. 10x Genomics shares dropped 15% after hours, following a 7.7% drop in the regular session to close at $43.29. The company said it expects second-quarter revenue of $114.5 million, a decline of 1% from last year's $115.8 million. Analysts surveyed by FactSet had estimated revenue of $127.7 million. Back in May, the company reaffirmed its full-year revenue forecast of $600 million to $630 million, while the Street expects $610.9 million.



(END) Dow Jones Newswires

07-14-22 1631ET

Copyright (c) 2022 Dow Jones & Company, Inc.